Stockreport

Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

Galecto, Inc.  (GLTO) 
PDF DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with [Read more]